Would you like me to look up Biogen’s specific patent holdings related to ofatumumab (Biogen Idec asignee), or are you after the overall patent landscape for ofatumumab (HuMax-CD20) including Genmab, GSK, etc.?
A few clarifying questions to proceed accurately:
- Jurisdiction(s): US, Europe (EPO), PCT/WIPO, or others?
- Timeframe: any particular years you care about?
- Output: a short list of Biogen-owned patent documents (numbers, titles, status) or a broader landscape summary with key families and status?
What I can tell you right now, at a high level:
- Ofatumumab is a human anti-CD20 monoclonal antibody that targets a CD20 epitope distinct from rituximab. It was developed by Genmab and has been associated with collaboration/licensing arrangements with multiple companies over the years.
- The patent space around ofatumumab includes multiple families covering: the antibody sequence/binding, methods of production, formulations, and therapeutic uses (various B-cell malignancies and autoimmune indications). There are patent families filed in the US, Europe, and internationally (WO/PCT publications).
- Biogen (Biogen Idec) has been involved in collaborations in the broader immunology/antibody space, so there may be Biogen-assigned patents or co-owned families related to ofatumumab in some jurisdictions. However, to give you an accurate list of Biogen-specific patents, I need to look up the exact assignee records and publication numbers for the jurisdictions and time span you care about.
If you want, I can:
- Search USPTO, EPO, WIPO (PCT), and other relevant databases for Biogen asignee patents mentioning ofatumumab or HuMax-CD20.
- Return a concise list: patent numbers/publishing dates, titles, assignees, and current legal status (pending/granted/expired).
- Provide a simple summary of the Biogen-related patent family (scope and expiration) and note any overlapping or related families from Genmab/GSK/others.
Tell me your preferred jurisdiction(s) and time window, and I’ll pull the Biogen-specific patent results and summarize them clearly. If you’d like a general non-Biogen overview first, I can provide that too. And as a reminder, for legal interpretation and freedom-to-operate opinions you’ll want a patent attorney.